Boston Scientific Corporation $BSX Shares Sold by BI Asset Management Fondsmaeglerselskab A S

Key Points

• BI Asset Management Fondsmaeglerselskab A S cut its Boston Scientific stake by 36.5% in the fourth quarter, selling 75,164 shares and leaving it with 130,516 shares worth about $12.4 million.
• Boston Scientific has continued to attract mixed but generally positive analyst attention: several firms recently trimmed price targets, but the stock still carries a Moderate Buy consensus with an average target price of $85.92.
• The company reported solid quarterly results, including EPS of $0.80 and revenue of $5.20 billion, and its board approved a $5 billion share buyback plan, signaling confidence in the stock’s value.

BI Asset Management Fondsmaeglerselskab A S decreased its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 36.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 130,516 shares of the medical equipment provider's stock after selling 75,164 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Boston Scientific were worth $12,445,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. FWL Investment Management LLC acquired a new stake in Boston Scientific in the second quarter worth about $26,000. Murphy & Mullick Capital Management Corp lifted its holdings in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 170 shares during the period. Colonial Trust Co SC lifted its holdings in Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 231 shares during the period. Bangor Savings Bank lifted its holdings in Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 142 shares during the period. Finally, Board of the Pension Protection Fund acquired a new stake in Boston Scientific in the fourth quarter worth about $29,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Analysts Set New Price Targets

BSX has been the subject of several research analyst reports. Jefferies Financial Group reduced their price objective on shares of Boston Scientific from $110.00 to $100.00 and set a "buy" rating for the company in a report on Wednesday, April 22nd. Weiss Ratings downgraded shares of Boston Scientific from a "hold (c)" rating to a "hold (c-)" rating in a report on Wednesday, May 13th. Wall Street Zen downgraded shares of Boston Scientific from a "buy" rating to a "hold" rating in a report on Saturday, March 28th. Mizuho dropped their price target on shares of Boston Scientific from $115.00 to $90.00 and set an "outperform" rating on the stock in a research report on Monday, April 13th. Finally, Robert W. Baird set a $70.00 price target on shares of Boston Scientific in a research report on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of "Moderate Buy" and an average target price of $85.92.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Canaccord reiterated a Buy rating on Boston Scientific, even though it trimmed its price target slightly to $70 from $71, signaling continued confidence in the company’s long-term outlook. Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?
• Positive Sentiment: Truist also kept a Buy rating, though it cut its price target to $64 from $85, suggesting analysts still see meaningful upside despite a more cautious valuation view. Benzinga
• Positive Sentiment: The company announced plans for a $138 million medical device distribution facility in Indiana, which should expand operations and add 300 jobs, a sign of ongoing investment in growth and logistics capacity. Boston Scientific to open $138M medical device distribution facility in Indiana, adding 300 jobs
• Neutral Sentiment: Boston Scientific’s last reported quarter was strong, with revenue of $5.20 billion and EPS of $0.80 beating expectations, but the company also cut guidance due to stronger competition in cardiac devices and slower Watchman growth, creating a mixed fundamental backdrop. How Investors May Respond To Boston Scientific (BSX) Strong Q1 Beat But Cut Guidance On Watchman Growth
• Neutral Sentiment: Recent market commentary noted BSX has been trading above market averages on some sessions, but also lagging some peers, reflecting choppy investor sentiment rather than a clear trend. Boston Scientific Corp. stock underperforms Thursday when compared to competitors despite daily gains
• Negative Sentiment: The repeated reductions in price targets from analysts, including Truist and Canaccord, suggest expectations have reset lower, which can weigh on sentiment even when ratings remain positive. Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director David C. Habiger bought 2,250 shares of the stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the purchase, the director directly owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Edward J. Ludwig bought 3,580 shares of the stock in a transaction on Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 9,800 shares of company stock valued at $554,012 in the last 90 days. 0.34% of the stock is currently owned by corporate insiders.

Boston Scientific Price Performance

NYSE BSX opened at $48.66 on Friday. The stock's 50-day moving average price is $58.11 and its two-hundred day moving average price is $76.70. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The company has a market cap of $72.32 billion, a PE ratio of 20.36, a PEG ratio of 0.91 and a beta of 0.56. Boston Scientific Corporation has a 1 year low of $47.17 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business's revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, analysts predict that Boston Scientific Corporation will post 3.37 EPS for the current year.

Boston Scientific announced that its Board of Directors has approved a stock buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's board believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.